Project: A novel diagnostic Biosensor for ALK-targeted therapy of non-small cell lung cancer (NSCLC)
| Acronym | BIOSTAR17 (Reference Number: 11375) |
| Duration | 01/10/2017 |
| Project Topic | Worldwide, lung cancer is the leading cause of cancer-related deaths (20% of total) with NSCLC as the most common type. BIOSTAR aims to market an innovative chip-based biosensor as companion diagnostic (CD) for the detection of the EML4-ALK biomarker as a prerequisite for the selection and the subsequent monitoring of ALK-targeted therapy in NSCLC treatment. Our biosensor will be superior to conventional detection methods by combining high-sensitivity, cost-effectiveness and usability. |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 7 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | InnoPharmaScreen Inc. | Coordinator | Korea, Republic of |
| 2 | ASAN Medical Center | Partner | Korea, Republic of |
| 3 | AptaIT GmbH | Partner | Germany |
| 4 | NeoVentures Biotechnology Inc. | Partner | Canada |
| 5 | Fraunhofer Gesellschaft | Partner | Germany |